BMY Q2 2026 Earnings Call Summary

Summary of Bristol-Myers Squibb Q2 2026 Earnings Call

1. Key Financial Results and Metrics

Total Revenue: Increased 5% year-over-year to approximately $13 billion.
Growth Portfolio Revenue: Rose 14% to $7.6 billion, now representing nearly 60% of total revenue.
Eliquis Revenue: Up 21% to approximately $4.5 billion, driven by strong demand and market share gains.
Gross Margin: Reported at 71.4%.
Diluted EPS: $2.04 for the quarter.
Operating Cash Flow: Approximately $3.4 billion generated.
Cash Position: Approximately $11.5 billion in cash equivalents and marketable securities.

2. Strategic Updates and Business Highlights

Strong Portfolio Performance: Key products such as Reblozyl, Breyanzi, Camzyos, Opdualag, and Qvantig achieved double-digit growth, with Breyanzi growing 41% and Camzyos 59%.
Pipeline Advancements: Positive Phase III data for mezigdomide in multiple myeloma and ongoing development in various therapeutic areas including oncology and neurology.
AI Integration: Continued expansion of AI capabilities across research and operations to enhance productivity and decision-making.
Business Development Focus: Emphasis on identifying opportunities in therapeutic areas aligned with BMS's expertise, particularly in innovative modalities.

3. Forward Guidance and Outlook

Increased Guidance: Full-year 2026 revenue and adjusted EPS guidance raised based on strong first-half results.
Eliquis Growth: Expected growth of 20% to 25% for Eliquis, with a less pronounced decline in the legacy portfolio projected at 4% to 6%.
Upcoming Milestones: Anticipation of pivotal data readouts across multiple programs, including iberdomide and mezigdomide, with PDUFA dates set for May 2027 and August 2027, respectively.

4. Bad News, Challenges, or Points of Concern

Pipeline Delays:
- Milvexian's atrial fibrillation study readout pushed to Q1 2027 due to slower-than-expected event recruitment.
- Cobenfy's ADEPT studies also delayed, with top-line data expected in early 2027.
Legacy Portfolio Decline: Despite Eliquis's growth, the overall legacy portfolio is facing challenges, particularly with the impact of generics on Revlimid.
Market Competition: Increased competition in the IPF market, particularly with the successful launch of JASCAYD, raises the bar for new entrants like admilparant.

5. Notable Q&A Insights

Milvexian's Potential: Discussion on the importance of achieving noninferiority in efficacy compared to Eliquis, with expectations for a favorable safety profile.
Cobenfy's Market Strategy: Emphasis on educating physicians about proper dosing and titration to maximize patient outcomes.
Business Development Strategy: Focus on acquiring innovative therapies that align with BMS’s existing strengths, particularly in oncology and neuroscience.
Confidence in Pipeline: Management expressed strong confidence in the ongoing clinical programs and the potential for new therapies to address unmet medical needs.

Overall, Bristol-Myers Squibb reported a solid quarter with strong growth in its portfolio while navigating challenges in its pipeline and legacy products. The company remains focused on strategic investments and maintaining financial flexibility to support future growth.

BMY — Bristol-Myers Squibb Company